{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:10:16Z","timestamp":1789431016720,"version":"build-2803163510"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We evaluated the safety and efficacy of oral treprostinil in preventing progression of SSc-associated calcinosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This prospective open-label study enrolled 12 SSc patients meeting 2013 ACR\/EULAR classification criteria with confirmed clinical and radiographic evidence of one or more calcinosis deposit in the hands. Patients received oral treprostinil for 1\u2009year. Primary endpoints were safety\/tolerability and percentage of patients without radiographic progression of calcinosis at 1\u2009year (&amp;lt;25% increase in Scleroderma Clinical Trials Consortium radiographic score). Secondary endpoints included 1-year changes in Scleroderma HAQ (SHAQ), Cochin Hand Functional Scale, Medical Outcomes Survey Short Form 36 (SF-36), Raynaud Condition Score and patient\/physician assessment of calcinosis severity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twelve female patients were enrolled, half with diffuse cutaneous disease; median age was 55\u2009years (range 35\u201368\u2009years). Five patients completed the study. Seven patients withdrew due to intolerable adverse effects (n\u2009=\u20093), intercurrent unrelated illness (n\u2009=\u20092, cirrhosis, cancer), progressive SSc (n\u2009=\u20091) and personal reasons (n\u2009=\u20091). Most patients developed headaches and gastrointestinal adverse effects. Four of 11 (36%) patients with 1-year follow-up hand radiographs experienced progression of calcinosis. Of five who completed treatment, calcinosis was stable in four (80%) with progression in one. Based on SF-36 Physical and Mental Component and Domain scores, transition question and SF-6D utility score, all patients who finished the trial reported overall improvement or no change compared with baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Oral treprostinil was poorly tolerated in SSc patients with calcinosis. Of five patients who completed treatment, most (80%) had documented stability of calcinosis on hand radiographs at 1\u2009year.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>ClinicalTrials.gov identifier<\/jats:title>\n                  <jats:p>NCT02663895.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab810","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T03:14:10Z","timestamp":1635304450000},"page":"2441-2449","source":"Crossref","is-referenced-by-count":13,"title":["A pilot study to evaluate the safety and efficacy of treprostinil in the treatment of calcinosis in systemic sclerosis"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-4910","authenticated-orcid":false,"given":"Melody P","family":"Chung","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Johns Hopkins University , Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Valenzuela","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, Pontificia Universidad Cat\u00f3lica de Chile , Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Catanese","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Radiology, Stanford University School of Medicine , Stanford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fiorentino","sequence":"additional","affiliation":[{"name":"Department of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[{"name":"Division of Immunology and Rheumatology, Stanford University School of Medicine , Palo Alto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorinda","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of Immunology and Rheumatology, Stanford University School of Medicine , Palo Alto"},{"name":"Division of Immunology and Rheumatology, VA Palo Alto Health Care System , Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"2022072312084616200_keab810-B1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/BOR.0000000000000539","article-title":"Calcinosis in scleroderma","volume":"30","author":"Valenzuela","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2022072312084616200_keab810-B2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.semarthrit.2016.05.008","article-title":"Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: a Scleroderma Clinical Trials Consortium study","volume":"46","author":"Valenzuela","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2022072312084616200_keab810-B3","article-title":"Change in calcinosis over 1 year using the SCTC radiologic scoring system for calcinosis of the hands in patients with systemic sclerosis [abstract]","volume":"71(Suppl 10","author":"Valenzuela","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022072312084616200_keab810-B4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/BOR.0b013e32834ff5cd","article-title":"Soft tissue and subcutaneous calcification in connective tissue diseases","volume":"24","author":"Chander","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"2022072312084616200_keab810-B5","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.semarthrit.2011.11.007","article-title":"Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature","volume":"41","author":"Daoussis","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"2022072312084616200_keab810-B6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/ard.2010.134304","article-title":"Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022072312084616200_keab810-B7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.semarthrit.2010.06.008","article-title":"Hand radiological damage in systemic sclerosis: comparison with a control group and clinical and functional correlations","volume":"40","author":"Koutaissoff","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"2022072312084616200_keab810-B8","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1093\/rheumatology\/kes214","article-title":"Acro-osteolysis in systemic sclerosis is associated with digital ischaemia and severe calcinosis","volume":"51","author":"Johnstone","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2022072312084616200_keab810-B9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.semarthrit.2020.06.007","article-title":"Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis","volume":"50","author":"Valenzuela","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2022072312084616200_keab810-B10","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40262-016-0409-0","article-title":"A comprehensive review of treprostinil pharmacokinetics via four routes of administration","volume":"55","author":"Kumar","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2022072312084616200_keab810-B11","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaad.2006.02.004","article-title":"A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis","volume":"54","author":"Chung","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2022072312084616200_keab810-B12","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3899\/jrheum.151437","article-title":"The recurrence of digital ulcers in patients with systemic sclerosis after discontinuation of oral treprostinil","volume":"43","author":"Shah","year":"2016","journal-title":"J Rheumatol"},{"key":"2022072312084616200_keab810-B13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5301\/jsrd.5000232","article-title":"Digital ulcers in Ssc treated with oral treprostinil: a randomized, double-blind, placebo-controlled study with open-label follow-up","volume":"2","author":"Seibold","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"2022072312084616200_keab810-B14","doi-asserted-by":"crossref","first-page":"2045894018770654","DOI":"10.1177\/2045894018770654","article-title":"Dosing characteristics of oral treprostinil in real-world clinical practice","volume":"8","author":"Balasubramanian","year":"2018","journal-title":"Pulm Circ"},{"key":"2022072312084616200_keab810-B15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1586\/14737167.5.3.317","article-title":"Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies","volume":"5","author":"Strand","year":"2005","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2022072312084616200_keab810-B16","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3899\/jrheum.110392","article-title":"It\u2019s good to feel better but it\u2019s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10","volume":"38","author":"Strand","year":"2011","journal-title":"J Rheumatol"},{"key":"2022072312084616200_keab810-B17","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2011-200387","article-title":"Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment","volume":"71","author":"Strand","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022072312084616200_keab810-B18","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1136\/ard.2009.115550","article-title":"Use of \u201cspydergrams\u201d to present and interpret SF-36 health-related quality of life data across rheumatic diseases","volume":"68","author":"Strand","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022072312084616200_keab810-B19","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1524-4733.2008.00352.x","article-title":"Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available)","volume":"11","author":"Ara","year":"2008","journal-title":"Value Health"},{"key":"2022072312084616200_keab810-B20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1524-4733.2008.00428.x","article-title":"Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available","volume":"12","author":"Ara","year":"2009","journal-title":"Value Health"},{"key":"2022072312084616200_keab810-B21","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"key":"2022072312084616200_keab810-B22","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"key":"2022072312084616200_keab810-B23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/FJC.0000000000000039","article-title":"Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers","volume":"63","author":"Jones","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022072312084616200_keab810-B24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab810\/41174279\/keab810.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2441\/45051863\/keab810.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2441\/45051863\/keab810.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T12:09:05Z","timestamp":1658578145000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/6\/2441\/6414200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,10,29]]},"published-print":{"date-parts":[[2022,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab810","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,10,29]]}}}